Fund managers have forecast an M&A boom for the biotech sector following Donald Trump's win in the US Presidential Election, but have warned of future uncertainty for wider healthcare services companies in areas such as Obamacare.
In the 24 hours following the US election result, healthcare and biotech-focused investment trusts rebounded after facing significant headwinds in the run-up to the vote, as the Nasdaq Biotechnology index soared 9%. The Biotech Growth, Worldwide Healthcare and International Biotechnology trusts were the top three biggest risers in share price terms in the investment company universe, up by as much as 9.4% between close of business on the 8 and 9 November, as the threat of a Hillary Clinton presidency was lifted. Source's Biotech ETF almost doubles assets post-US election Daniel Mah...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
